A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00555256 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: sunitinib and rapamycin (Drug will be held)

Sponsor

Washington University School of Medicine

Collaborators

[object Object]